Bristol-Myers Squibb’s first quarter disappoints

Markus MacGill

pharmaphorum

The first-quarter financial performance by Bristol-Myers Squibb has fallen short of analysts’ predictions.

The company saw a fall in first-quarter profits versus last year by 45 per cent as cardiovascular products have come off patent.

The news comes in a week when AstraZeneca also suffered lower profits thanks to generics competition (https://pharmaphorum.com/2013/04/25/astrazeneca-profit-down-by-quarter/). GlaxoSmithKline also reported a drop in first-quarter profits this week (https://pharmaphorum.com/2013/04/24/glaxosmithkline-profit-down-selling-off-brands/).

“The first quarter was a good start to an important year in which our focus will be on the growth of existing brands, the execution of new launches and the continued delivery of a diverse and sustainable pipeline”

Lamberto Andreotti, chief executive, Bristol-Myers Squibb.

There was a 27 per cent drop in income to $3.83 billion for New York-based Bristol-Myers, against analysts’ estimation of $3.87 billion in sales.

&nbsp,

pharmaphorum-google-plus

Related news:

Bristol-Myers Profit Misses Estimates as New Drugs Are Focus (Bloomberg)

Bristol-Myers Net Drops on Lower Sales of Heart Drugs (Fox Business)

Reference links:

Bristol-Myers Squibb press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.